Table 4.
The clinical trials of approved HDAC inhibitors
| Conditions | Interventions | Phase | N | NCT number | Status |
|---|---|---|---|---|---|
| Vorinostat | |||||
| CTCL | Vorinostat | 1 | 10 | NCT00771472 | Completed |
| Advanced CTCL | Vorinostat | 2 | 74 | NCT00091559 | Completed |
| ND T-cell lymphoma | Vorinostat+CHOP | 1/2 | 14 | NCT00787527 | Completed |
| ND T-cell lymphoma, MCL, R/R other types of lymphoma | Vorinostat+Rituximab+Ifosfamide+Carboplatin+Etoposide | 1/2 | 29 | NCT00601718 | Completed |
| ENKT | Vorinostat+Azacitidine | 1 | 18 | NCT00336063 | Active, not recruiting |
| Low-grade NHL | Vorinostat | 2 | 37 | NCT00253630 | Completed |
| Indolent NHL | Vorinostat+Rituximab | 2 | 30 | NCT00720876 | Completed |
| R/R NHL, AML, ALL, CML | Vorinostat+Decitabine | 1 | 80 | NCT00275080 | Completed |
| Relapsed NHL | Vorinostat+Combination Chemotherapy | 2 | 30 | NCT04220008 | Not yet recruiting |
| Indolent B-cell NHL, MCL | Vorinostat | 2 | 56 | NCT00875056 | Completed |
| R/R MCL, DLBCL | Vorinostat+Bortezomib | 2 | 65 | NCT00703664 | Completed |
| MCL, R/R B-NHL, R/R CLL | Vorinostat+Cladribine+Rituximab | 2 | 57 | NCT00764517 | Completed |
| ND stage II-IV DLBCL | Vorinostat+Rituximab+Combination Chemotherapy | 1/2 | 83 | NCT00972478 | Active, not recruiting |
| R/R DLBCL, FL, HL | Vorinostat+Pembrolizumab | 1 | 52 | NCT03150329 | Completed |
| R/R DLBCL | Vorinostat+Azacitidine | 1/2 | 17 | NCT01120834 | Completed |
| Relapsed DLBCL | Vorinostat | 2 | 18 | NCT00097929 | Completed |
| Elderly relapsed DLBCL | Vorinostat+Cyclophosphamide, Etoposide, Prednisone and Rituximab | 1/2 | 30 | NCT00667615 | Completed |
| R/R B-cell lymphoma | Vorinostat+Carfilzomib | 1 | 20 | NCT01276717 | Completed |
| R/R advanced HL | Vorinostat | 2 | 27 | NCT00132028 | Completed |
| HIV-related DLBCL, other aggressive B-cell lymphoma | Vorinostat+Rituximab+Combination Chemotherapy | 1/2 | 107 | NCT01193842 | Completed |
| Lymphoma | Vorinostat+Niacinamide+Etoposide | 1 | 40 | NCT00691210 | Completed |
| High-risk lymphoma | Vorinostat after stem cell transplantation | 1 | 23 | NCT00561418 | Completed |
| Relapsed lymphoma | Vorinostat | 1 | 10 | NCT00127140 | Completed |
| R/R lymphoma | Vorinostat+Gemcitabine+Busulfan+ Melphalan+Stem Cell Transplant | 1 | 78 | NCT01421173 | Completed |
| R/R lymphoma | Vorinostat+Alisertib | 1 | 34 | NCT01567709 | Completed |
| NHL after ASCT | Vorinostat+Bortezomib | 2 | 27 | NCT00992446 | Completed |
| ND MM | Vorinostat+Bortezomib+Lenalidomide+Dexamethasone | 1 | 30 | NCT01038388 | Completed |
| ND MM in maintenance treatment | Vorinostat+Lenalinomide | 3 | 4420 | NCT01554852 | Active, not recruiting |
| R-resistant MM | Vorinostat+Lenalinomide+Dexamethasone | 1/2 | 25 | NCT01502085 | Completed |
| R/R MM | Vorinostat+Bortezomib | 1 | 34 | NCT00111813 | Completed |
| R/R MM | Vorinostat+Bortezomib | 1 | 9 | NCT00858234 | Completed |
| R/R MM | Vorinostat+Bortezomib | 1 | 40 | NCT00310024 | Completed |
| R/R MM | Vorinostat+Bortezomib | 2 | 143 | NCT00773838 | Completed |
| R/R MM | Vorinostat+Lenalinomide+Dexamethasone | 1 | 31 | NCT00642954 | Completed |
| R/R MM | Vorinostat+Bortezomib+Doxorubicin+Dexamethasone | 1/2 | 34 | NCT01394354 | Completed |
| R/R MM | Vorinostat+Carfilzomib+Lenalidomide+Dexamethasone | 1/2 | 17 | NCT01297764 | Active, not recruiting |
| MM after ASCT | Vorinostat+Lenalinomide | 1 | 19 | NCT00729118 | Completed |
| MM after ASCT | Vorinostat+Bortezomib | 2 | 31 | NCT00839956 | Completed |
| MM | Vorinostat+Bortezomib | 3 | 637 | NCT00773747 | Completed |
| MM | Vorinostat+Bortezomib+ Dexamethasone | 2 | 16 | NCT01720875 | Completed |
| Young ND AML | Vorinostat/+Idarubicin and Cytarabine v.s. Cytarabine+Daunorubicin Hydrochloride | 3 | 754 | NCT01802333 | Completed |
| ND AML, MDS | Vorinostat+Azacitidine | 2 | 110 | NCT00948064 | Completed |
| R/R AML | Vorinostat+Temozolomide | 2 | 23 | NCT01550224 | Completed |
| R/R AML, MDS | Vorinostat+Decitabine+Cytarabine | 1 | 17 | NCT01130506 | Completed |
| R/R AML, ALL, CML | Vorinostat+Flavopiridol | 1 | 24 | NCT00278330 | Completed |
| R/R AML | Vorinostat+Decitabine+Fludarabine+Cytarabine+Filgrastim (G-CSF) | 1 | 37 | NCT03263936 | Completed |
| R/R or poor prognosis AML, MDS, CML, ALL | Vorinostat+Decitabine | 1 | 50 | NCT00357708 | Completed |
| R/R AML | Vorinostat+venetocla+azacitidine+Cytarabine+Fludarabine+Filgrastim | 1 | 40 | NCT05317403 | Not yet recruiting |
| Elder R/R AML | Vorinostat+Azacitidine+Gemtuzumab Ozogamicin | 1/2 | 52 | NCT00895934 | Completed |
| Poor-risk AML, high-risk MDS | Vorinostat+Sorafenib | 1 | 15 | NCT00875745 | Completed |
| Pediatric or young adult AML, MDS | Vorinostat+Azacytidine after alloSCT | 1 | 15 | NCT03843528 | Recruiting |
| Complex/poor-risk cytogenetics AML or FLT3-ITD | Vorinostat+Sorafenib+Bortezomib | 1/2 | 37 | NCT01534260 | Completed |
| AML | Vorinostat | 2 | 37 | NCT00305773 | Completed |
| AML, MDS | Vorinostat+Decitabine | 1 | 71 | NCT00479232 | Completed |
| AML, MDS | Vorinostat+Azacitidine | 1/2 | 135 | NCT00392353 | Active, not recruiting |
| AML, high-risk MDS | Vorinostat/+Azacitidine | 2 | 260 | NCT01617226 | Completed |
| AML, high-risk MDS | Vorinostat+Idarubicin+Cytarabine | 2 | 106 | NCT00656617 | Completed |
| R/R leukemia, MDS | Vorinostat+Idarubicin | 1 | 40 | NCT00331513 | Completed |
| AML before alloSCT | Vorinostat+Fludarabine Phosphate+Clofarabine+Busulfan | 1 | 70 | NCT02083250 | Completed |
| High-risk MDS | Vorinostat+Low Dose Cytarabine | 1/2 | 52 | NCT00776503 | Completed |
| High-risk MDS before CD3-/CD19- NK Cells Infusion | Vorinostat+Decitabine | 2 | 9 | NCT01593670 | Completed |
| High-risk MDS, CMML | Vorinostat/Lenalidomide/- +Zzacitidine | 2 | 282 | NCT01522976 | Completed |
| Acute leukemia, MDS, MPN | Vorinostat+Cytarabine+Etoposide | 1 | 25 | NCT00357305 | Completed |
| Infant ALL | Vorinostat+Bortezomib+Chemotherapy | 1/2 | 50 | NCT02553460 | Active, not recruiting |
| Accelerated phase or blastic phase CML, ALL | Vorinostat+Dasatinib | 1 | 5 | NCT00816283 | Completed |
| ND CLL/SLL | Vorinostat+Fludarabine+Cyclophosphamide+Rituximab | 1/2 | 40 | NCT00918723 | Completed |
| Reduced intensity, related donor stem cell transplant | Vorinostat+Tacrolimus+Mycophenolate | 1/2 | 61 | NCT00810602 | Completed |
| Unrelated stem cell transplant | Vorinostat+Tacrolimus+Methotrexate | 2 | 26 | NCT01790568 | Completed |
| AlloSCT | Vorinostat+Tacrolimus+Methotrexate+Mycophenolate Mofetil+Cyclophosphamide | 1/2 | 49 | NCT03842696 | Recruiting |
| Stem cell transplant | Vorinostat+Tacrolimus+Methotrexate | 2 | 12 | NCT01789255 | Completed |
| Belinostat | |||||
| PTCL | Belinostat+CHOP | 1 | 23 | NCT01839097 | Completed |
| R/R PTCL | Belinostat | 2 | 129 | NCT00865969 | Completed |
| R/R BL, DLBCL | Belinostat | 2 | 22 | NCT00303953 | Completed |
| R/R NHL | Belinostat+Carfilzomib | 1 | 19 | NCT02142530 | Completed |
| Relapsed aggressive high-risk lymphoma | Belinostat+Rituximab+Yttrium Y 90 Ibritumomab Tiuxetan | 2 | 5 | NCT01686165 | Completed |
| Adult T-cell leukemia/lymphoma | Belinostat+Zidovudine | 2 | 20 | NCT02737046 | Recruiting |
| R/R AML | Belinostat+Pevonedistat | 1 | 30 | NCT03772925 | Recruiting |
| AML unsuitable for standard intensive therapy | Belinostat+Idarubicin | 1/2 | 41 | NCT00878722 | Completed |
| AML | Belinostat | 2 | 12 | NCT00357032 | Completed |
| R/R acute leukemia, MDS | Belinostat+Bortezomib | 1 | 41 | NCT01075425 | Completed |
| AML, ALL, CML, MDS | Belinostat+Azacitidine | 1 | 56 | NCT00351975 | Completed |
| MDS | Belinostat | 2 | 21 | NCT00357162 | Completed |
| Advanced MM | Belinostat+Dexamethsone | 2 | 25 | NCT00131261 | Completed |
| Panobinostat | |||||
| R/R MM | Panobinostat+Bortezomib+Dexamethasone | 3 | 767 | NCT01023308 | Completed |
| R/R MM | Panobinostat+Bortezomib+Dexamethasone | 2 | 249 | NCT02654990 | Active, not recruiting |
| R/R MM | Panobinostat+Bortezomib+Dexamethasone | 2 | 31 | NCT02290431 | Completed |
| Relapsed and bortezomib-refractory MM | Panobinostat+Bortezomib+Dexamethasone | 2 | 55 | NCT01083602 | Completed |
| R/R MM | Panobinostat+Bortezomib | 1 | 62 | NCT00532389 | Completed |
| R/R MM | Panobinostat+Carfilzomib | 1/2 | 80 | NCT01496118 | Completed |
| R/R MM | Panobinostat+Carfilzomib | 1 | 32 | NCT01549431 | Completed |
| R/R MM | Panobinostat+Carfilzomib | 1 | 46 | NCT01301807 | Active, not recruiting |
| R/R MM | Panobinostat+Lenalidomide+Dexamethasone | 2 | 32 | NCT01651039 | Completed |
| R/R MM | Panobinostat+Bortezomib+Lenalidomide+Dexamethasone | 1 | 21 | NCT01965353 | Completed |
| R/R MM | Panobinostat+Daratumumab+Bortezomib+Dexamethasone | 1 | 27 | NCT04956302 | Recruiting |
| Relapsed MM | Panobinostat+Melphalan | 1/2 | 40 | NCT00743288 | Completed |
| Adult MM | Panobinostat+Lenalidomide+Dexamethasone | 1 | 46 | NCT00532675 | Completed |
| ND transplant-eligible MM | Panobinostat+Bortezomib+Lenalidomide+Dexamethasone | 1 | 77 | NCT01440582 | Completed |
| R/R MM before autoSCT | Panobinostat+Gemcitabine+Busulfan+Melphalan | 2 | 83 | NCT02506959 | Active, not recruiting |
| MM after autoSCT | Panobinostat | 2 | 30 | NCT02722941 | Active, not recruiting |
| Recurrent MM, lymphoma | Panobinostat+Everolimus | 1/2 | 124 | NCT00918333 | Completed |
| R/R MM, lymphoma | Panobinostat+Everolimus | 1 | 11 | NCT00962507 | Completed |
| Refractory CTCL | Panobinostat | 2 | 139 | NCT00425555 | Completed |
| R/R PTCL, ENKT | Panobinostat+Bortezomib | 2 | 25 | NCT00901147 | Completed |
| R/R MCL | Panobinostat+Bortezomib | 1 | 3 | NCT01504776 | Completed |
| R/R DLBCL | Panobinostat | 2 | 35 | NCT01523834 | Completed |
| R/R WM | Panobinostat | 2 | 39 | NCT00936611 | Completed |
| R/R NHL | Panobinostat | 2 | 41 | NCT01261247 | Completed |
| R/R classical HL | Panobinostat | 2 | 129 | NCT00742027 | Completed |
| R/R HL | Panobinostat+Lenalidomide | 2 | 24 | NCT01460940 | Completed |
| Relapsed HL | Panobinostat/+Ifosfamide+Carboplatin+Etoposide | 1/2 | 62 | NCT01169636 | Completed |
| HL maintenance | Panobinostat | 3 | 41 | NCT01034163 | Completed |
| R/R lymphoma | Panobinostat+Everolimus | 1/2 | 31 | NCT00967044 | Completed |
| Pediatric lymphoma, AML, ALL | Panobinostat for lymphoma, Panobinostat+Cytarabine for Leukemia | 1 | 30 | NCT01321346 | Completed |
| High-risk AML, MDS after HSCT | Panobinostat | 3 | 52 | NCT04326764 | Active, not recruiting |
| AML younger than 65 years old | Panobinostat+Chemotherapy | 1 | 40 | NCT01242774 | Completed |
| ND AML older than 65 years old | Panobinostat+Idarubicin+Cytarabine | 1/2 | 46 | NCT00840346 | Completed |
| ND AML, advanced MDS | Panobinostat+Daunorubicin+Cytarabine | 1 | 29 | NCT01463046 | Completed |
| Refractory AML | Panobinostat | 2 | 59 | NCT00880269 | Completed |
| R/R AML | Panobinostat+Azacitidine+Mitoxantrone | 1 | 59 | NCT01055483 | Completed |
| AML, MDS | Panobinostat+Decitabine | 1/2 | 52 | NCT00691938 | Completed |
| AML, MDS, CMML | Panobinostat+Azacitidine | 1 | 10 | NCT01613976 | Completed |
| AML, MDS, CMML | Panobinostat+Azacitidine | 1/2 | 113 | NCT00946647 | Completed |
| Previously treated chronic phase CML | Panobinostat+Imatinib | 1 | 9 | NCT00686218 | Completed |
| MF | Panobinostat+Ruxolitinib | 1 | 61 | NCT01433445 | Completed |
| MF | Panobinostat+Ruxolitinib | 1/2 | 20 | NCT01693601 | Completed |
| MF, PV, GVHD, AML | Panobinostat/+Ruxolitinib | 4 | 298 | NCT02386800 | Recruiting |
| Advanced hematologic malignancies | Panobinostat | 1/2 | 175 | NCT00621244 | Completed |
| AlloSCT | Panobinostat+Sirolimus+Tacrolimus | 2 | 42 | NCT02588339 | Completed |
| AlloSCT | Panobinostat+Corticosteroids | 1/2 | 22 | NCT01111526 | Completed |
| Chidamide | |||||
| ND PTCL | Chidamide+CHOP | 1 | 30 | NCT02809573 | Completed |
| ND PTCL | Chidamide+CHOEP | 1/2 | 100 | NCT02987244 | Recruiting |
| ND PTCL | Chidamide+Azacitidine/+CHOP | 3 | 107 | NCT05075460 | Not yet recruiting |
| ND PTCL unfit for conventional chemotherapy | Chidamide+Azacitidine | 2 | 28 | NCT04480125 | Recruiting |
| R/R PTCL | Chidamide+Parsaclisib | 1/2 | 28 | NCT05083208 | Not yet recruiting |
| R/R PTCL | Chidamide+Lenalidomide | 2 | 44 | NCT04329130 | Recruiting |
| R/R PTCL | Chidamide+Sintilimab | 2 | 51 | NCT04512534 | Recruiting |
| R/R PTCL | Chidamide+Sintilimab+Azacitidine | 2 | 30 | NCT04052659 | Not yet recruiting |
| R/R PTCL | Chidamide v.s. Mitoxantrone Hydrochloride Liposome Injection | 3 | 190 | NCT04668690 | Not yet recruiting |
| ND AITL | Chidamide+CHOP | 2 | 23 | NCT03853044 | Active, not recruiting |
| R/R ATIL | Chidamide+Azacitidine | 2 | 20 | NCT05179213 | Not yet recruiting |
| R/R AITL | Chidamide+Sintilimab | 2 | 83 | NCT04831710 | Not yet recruiting |
| R/R AITL | Chidamide+Rituximab+Lenalidomide | NA | 26 | NCT04319601 | Recruiting |
| ND ENKT | Chidamide+Sintilimab | 2 | 30 | NCT04994210 | Recruiting |
| R/R ENKT | Chidamide+Sintilimab | 1/2 | 40 | NCT03820596 | Completed |
| Stage I/II ENKT | Chidamide/+Gemcitabine+Cisplatin+Dexamethasone+Radiotherapy | NA | 76 | NCT04511351 | Recruiting |
| R/R CTCL | Chidamide+Sintilimab | 2 | 52 | NCT04296786 | Recruiting |
| T-NHL before autoSCT | Chidamide+Carmustine+Etoposide+Cytarabine+Melphalan | 2 | 23 | NCT05367856 | Not yet recruiting |
| ND double-expressor DLBCL | Chidamide/+RCHOP | 3 | 418 | NCT04231448 | Recruiting |
| R/R DLBCL | Chidamide+Rituximab+Anti-PD-1 Antibody | 2 | 27 | NCT05115409 | Not yet recruiting |
| R/R transplant-ineligible DLBCL | Chidamide+Rituximab+Gemcitabine+Oxaliplatin | 2 | 54 | NCT04022005 | Recruiting |
| R/R B-NHL | Chidamide | 2 | 100 | NCT03245905 | Recruiting |
| R/R B-NHL before CAR-T | Chidamide/+Fludarabine+Cyclophosphamide | 1/2 | 120 | NCT05370547 | Recruiting |
| Aggressive R/R B-NHL undergoing decitabine-primed tandem CD19/CD20 CAR-T | Chidamide v.s. Decitabine v.s. Chidamide+Decitabine | 1/2 | 80 | NCT04553393 | Recruiting |
| R/R NHL | Chidamide+Chiauranib | 1/2 | 9 | NCT03974243 | Completed |
| R/R NHL | Chidamide+Decitabine+Immune checkpoint inhibitors | 1/2 | 100 | NCT05320640 | Recruiting |
| NHL who relapsed after CAR-T | Chidamide+Decitabine | 1/2 | 100 | NCT04337606 | Recruiting |
| NHL | Chidamide | 1 | 13 | NCT02697552 | Completed |
| ND primary central nervous system lymphoma | Chidamide+Rituximab+Methotrexate | 2 | 51 | NCT04516655 | Not yet recruiting |
| R/R classical HL | Chidamide+Decitabine+Camrelizumab | 2 | 100 | NCT04233294 | Recruiting |
| Anti-PD-1 antibody-resistant classical HL | Chidamide/+Decitabine+Camrelizumab | 2 | 200 | NCT04514081 | Recruiting |
| Aggressive lymphoma | Chidamide+BEAC+autoSCT | 2 | 69 | NCT03629873 | Active, not recruiting |
| R/R MM | Chidamide+Lenalidomide+Dexamethasone | 2 | 25 | NCT03605056 | Not yet recruiting |
| Primary high-risk MM | Chidamide/+Bortezomib+Lenalidomide+Dexamethasone | 1/2 | 50 | NCT04025450 | Recruiting |
| CBF AML | Chidamide v.s. Cytarabine | 1/2 | 250 | NCT03031262 | Recruiting |
| R/R AML | Chidamide+Azacitidine+Venetoclax | 2 | 30 | NCT05305859 | Not yet recruiting |
| R/R AML | Chidamide+Cladribine | 2 | 31 | NCT05330364 | Recruiting |
| R/R AML | Chidamide+Decitabine+Priming IAG | 2 | 40 | NCT03985007 | Completed |
| R/R AML | Chidamide/+Azacitidine+HAG | 2 | 210 | NCT05029141 | Recruiting |
| AML after transplant | Chidamide+Azacitidine | 1/2 | 20 | NCT05270200 | Recruiting |
| T-ALL | Chidamide+Ruxolitinib | 1/2 | 50 | NCT05075681 | Recruiting |
| B-ALL undergoing haploidentical alloSCT | Chidamide+Ruxolitinib | 2 | 50 | NCT05088226 | Recruiting |
| Adult Ph-like ALL | Chidamide v.s. Dasatinib | 2/3 | 120 | NCT03564470 | Recruiting |
| HLH | Chidamide+VP-16+Methylprednisolone | NA | 20 | NCT05137522 | Recruiting |
| ENKT-HLH | Chidamide+Sintilimab v.s Azacitidine+Sintilimab v.s. L-DEP | 2 | 37 | NCT05008666 | Not yet recruiting |
| Steroid-resistant/steroid-dependent Severe cGVHD | Chidamide | 1/2 | 20 | NCT05140616 | Recruiting |
| Romidepsin | |||||
| Conditions | Interventions | Phase | Patients | NCT number | Status |
| ND PTCL | Romidepsin/+CHOP | 3 | 421 | NCT01796002 | Active, not recruiting |
| ND PTCL | Romidepsin+Lenalidomide | 2 | 35 | NCT02232516 | Active, not recruiting |
| ND PTCL | Romidepsin+CHOP | 1/2 | 37 | NCT01280526 | Completed |
| ND young nodal PTCL before HSCT | Romidepsin+CHOEP | 1/2 | 89 | NCT02223208 | Active, not recruiting |
| R/R PTCL | Romidepsin+Ixazomib | 1/2 | 11 | NCT03547700 | Active, not recruiting |
| R/R PTCL | Romidepsin+Carfilzomib | 1/2 | 50 | NCT03141203 | Completed |
| R/R PTCL | Romidepsin+Gemcitabine | 2 | 20 | NCT01822886 | Completed |
| R/R PTCL | Romidepsin+Pembrolizumab | 1/2 | 39 | NCT03278782 | Recruiting |
| R/R PTCL | Romidepsin+Ifosfamide+Carboplatin+Etoposide | 1 | 22 | NCT01590732 | Completed |
| Progressive or relapsed PTCL | Romidepsin | 2 | 131 | NCT00426764 | Completed |
| Progressive or relapsed PTCL | Romidepsin | 1/2 | 51 | NCT01456039 | Completed |
| PTCL, CTCL | Romidepsin | 2 | 131 | NCT00007345 | Completed |
| R/R mature TCL | Romidepsin+Venetoclax | 2 | 9 | NCT03534180 | Active, not recruiting |
| R/R TCL | Romidepsin+Tenalisib | 1/2 | 33 | NCT03770000 | Completed |
| R/R TCL | Romidepsin+Parsaclisib | 1 | 20 | NCT04774068 | Recruiting |
| R/R TCL | Romidepsin+Duvelisib v.s. Bortezomib+Duvelisib | 1 | 114 | NCT02783625 | Active, not recruiting |
| R/R TCL | Romidepsin+Azacitidine+Lenalidomide+Dexamethasone | 1 | 30 | NCT04447027 | Recruiting |
| R/R AITL | Romidepsin+Sintilimab | 2 | 83 | NCT04831710 | Not yet recruiting |
| R/R ENKT | Romidepsin | 1 | 16 | NCT01913119 | Completed |
| TCL | Romidepsin+Azacitidine+Duvelisib | 1 | 60 | NCT04639843 | Not yet recruiting |
| TCL, T-ALL after alloSCT | Romidepsin | 1 | 10 | NCT02512497 | Recruiting |
| Previously treated PTCL, DLBCL | Romidepsin+Gemcitabine+Dexamethasone+Cisplatin | 1 | 21 | NCT01846390 | Completed |
| CTCL | Romidepsin+Brentuximab Vedotin | 1 | 27 | NCT02616965 | Recruiting |
| R/R CTCL | Romidepsin+doxorubicin HCl liposomal | 1 | 24 | NCT01902225 | Completed |
| R/R CTCL | Romidepsin | 2 | 102 | NCT00106431 | Completed |
| T-NHL after autoSCT | Romidepsin maintenance | 2 | 47 | NCT01908777 | Active, not recruiting |
| R/R NHL | Romidepsin | 2 | 35 | NCT00077194 | Completed |
| R/R NHL | Romidepsin+Alisertib | 1 | 26 | NCT01897012 | Completed |
| R/R NHL | Romidepsin+Carfilzomib+Lenalidomide | 1/2 | 31 | NCT02341014 | Active, not recruiting |
| R/R aggressive lymphoma | Romidepsin+Gemcitabine+Oxaliplatin+Dexamethasone | 1 | 24 | NCT02181218 | Completed |
| R/R lymphoma, myeloma | Romidepsin+Lenalidomide | 1/2 | 62 | NCT01755975 | Active, not recruiting |
| R/R MM | Romidepsin | 2 | 50 | NCT00066638 | Completed |
| R/R AML | Romidepsin | 2 | 47 | NCT00062075 | Completed |
| R/R leukemia, MDS, MPN | Romidepsin+Decitabine | 1 | 36 | NCT00114257 | Completed |
| R/R CLL/SLL | Romidepsin+Bortezomib | 1 | 18 | NCT00963274 | Completed |
AITL angioimmunoblastic T-cell lymphoma, ALL acute lymphoblastic leukemia, alloSCT allogenic stem cell transplantation, AML acute myeloid leukemia, ASCT autologous stem cell transplantation, BL Burkitt’s lymphoma, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, CTCL cutaneous T-cell lymphoma/leukemia, DLBCL diffuse large B-cell lymphoma, ENKT extranodal NK/T-cell lymphoma, FL follicular lymphoma, GVHD graft-versus-host disease, HL Hodgkin lymphoma, ITD internal tandem duplication, MCL mantle cell lymphoma, MDS myelodysplastic syndrome, MF myelofibrosis, MM multiple myeloma, ND newly diagnosed, NHL non-Hodgkin lymphoma, PV polycythemia vera, PTCL peripheral T-cell lymphoma, R rituximab, R/R relapsed/refractory, SLL small lymphocytic lymphoma